In a Thursday session at BIO 2014 next week, attendees will get a lesson from a panel of experts on how to get a piece of the government funding available for companies developing medical countermeasures (MCMs). Read More
Despite the fact that the general markets took it on the chin toward the end of last week over concerns about unrest in Iraq and the resulting surge in energy prices, biotech companies did not follow suit. In fact, the period has seen the sector benefit from a steady flow of positive news flow to keep investors on side. Read More
